Technology area: Biotechnology & Pharmaceuticals
37 pending office actions • 25 art units • 34 examiners • 0 of 37 (0%) have an AI response strategy ready • 55 patents granted in the last 365 days
United States Department of Health and Human Services has 40 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 37 distinct examiners and 27 distinct art units, demonstrating broad prosecution activity across many examination assignments.
DAVIS, BRIAN J is the busiest examiner, with 2 pending office actions. The scale and dispersion favor centralized docket oversight, consistent claim-position management, and targeted responses for each examiner and art-unit context.
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (3%) |
| §101 + other | 5 (14%) |
| §103 only | 7 (19%) |
| §102 only | 2 (5%) |
| §112 only | 7 (19%) |
| Double-patenting + other | 3 (8%) |
| Multi-statute (no §101) | 12 (32%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, BRIAN J | 2 | 84.8% | -3.9% |
| DONOHUE, SEAN R | 2 | 41.4% | +21.0% |
| RAMIREZ, DELIA M | 2 | 65.1% | +56.3% |
| HILL, MYRON G | 1 | 66.1% | +20.7% |
| SPANGLER, JOSEPH RANKIN | 1 | 40.8% | +70.6% |
| GRIZER, CASSANDRA SENN | 1 | 70.0% | +48.0% |
| ZAHORIK, AMANDA MARY | 1 | 58.3% | +49.3% |
| BUCHANAN, BAILEY CHEYENNE | 1 | 42.9% | +57.1% |
| MEYERING, SHABANA SHABBEER | 1 | 68.5% | +45.1% |
| GAO, ASHLEY HARTMAN | 1 | 56.5% | +38.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042743 | METHODS TO PRODUCE VERY LONG CHAIN FATTY ACIDS (VLCFA) | DAVIS, BRIAN J | 187d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283516 | IMMUNOGENIC COMPOSITIONS | GRIZER, CASSANDRA SENN | 26d overdue |
| 17632783 | CANCER DETECTION AND CLASSIFICATION | BUCHANAN, BAILEY CHEYENNE | 8d overdue |
| 18026544 | CORONAVIRUS ANTIBODIES AND USES THEREOF | JADHAO, SAMADHAN JAISING | 27d |
| 18036112 | ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN | ZAHORIK, AMANDA MARY | 36d |
| 18720218 | NEXT GENERATION TRANSPOSOSOMES | SPANGLER, JOSEPH RANKIN | — |
| 18570579 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides for Drug Delivery Applications | DAVIS, BRIAN J | — |
| 17793083 | REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES | DONOHUE, SEAN R | — |
| 18836317 | THERMOACOUSTIC SENSOR WITH FLUID MIXING FOR MEASUREMENT OF ACOUSTIC POWER OF ULTRASOUND TRANSDUCERS OVER A WIDEFREQUENCY RANGE | MERCADO, ALEXANDER A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17214436 | IMMUNORESPONSIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF | MEYERING, SHABANA SHABBEER | 56d overdue |
| 18283516 | IMMUNOGENIC COMPOSITIONS | GRIZER, CASSANDRA SENN | 26d overdue |
| 17632783 | CANCER DETECTION AND CLASSIFICATION | BUCHANAN, BAILEY CHEYENNE | 8d overdue |
| 16450825 | NOVEL CRISPR ENZYMES AND SYSTEMS | RAMIREZ, DELIA M | 14d |
| 18036112 | ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN | ZAHORIK, AMANDA MARY | 36d |
| 17793089 | ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS AND THEIR USE IN HYPERPOLARIZED IMAGING | DONOHUE, SEAN R | 43d |
| 18799179 | CHIMERIC VECTORS | HILL, MYRON G | — |
| 18720218 | NEXT GENERATION TRANSPOSOSOMES | SPANGLER, JOSEPH RANKIN | — |
| Art Unit | Apps |
|---|---|
| 1671 | 3 |
| 1636 | 3 |
| 1614 | 2 |
| 1672 | 2 |
| 1618 | 2 |
| 1645 | 2 |
| 1658 | 2 |
| 1652 | 2 |
| 1656 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18799179 | CHIMERIC VECTORS | HILL, MYRON G | 1671 | §102§103DP | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18720218 | NEXT GENERATION TRANSPOSOSOMES | SPANGLER, JOSEPH RANKIN | 1656 | §101§102§112DP | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18570579 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides for Drug Delivery Applications | DAVIS, BRIAN J | 1614 | §102§112 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18283516 | IMMUNOGENIC COMPOSITIONS | GRIZER, CASSANDRA SENN | 1672 | §102§103§112 | Final Rejection | 26d overdue | Pending | Sep 22, 2023 |
| 18036112 | ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN | ZAHORIK, AMANDA MARY | 1636 | §102§103§112 | Non-Final OA | 36d | Pending | May 09, 2023 |
| 17793083 | REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES | DONOHUE, SEAN R | 1618 | §103§112 | Final Rejection | — | Pending | Jul 15, 2022 |
| 17793089 | ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS AND THEIR USE IN HYPERPOLARIZED IMAGING | DONOHUE, SEAN R | 1618 | §103 | Final Rejection | 43d | Pending | Jul 15, 2022 |
| 17632783 | CANCER DETECTION AND CLASSIFICATION | BUCHANAN, BAILEY CHEYENNE | 1682 | §101§102§103 | Final Rejection | 8d overdue | Pending | Feb 03, 2022 |
| 17214436 | IMMUNORESPONSIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF | MEYERING, SHABANA SHABBEER | 1635 | §103 | Final Rejection | 56d overdue | Pending | Mar 26, 2021 |
| 17274564 | METHODS FOR DECREASING INFLUENZA-INDUCED LETHALITY USING GASTRIN-RELEASING PEPTIDE (GRP) INHIBITORS OR GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) ANTAGONISTS | GAO, ASHLEY HARTMAN | 1678 | §103 | Final Rejection | — | Pending | Mar 09, 2021 |
| 18836317 | THERMOACOUSTIC SENSOR WITH FLUID MIXING FOR MEASUREMENT OF ACOUSTIC POWER OF ULTRASOUND TRANSDUCERS OVER A WIDEFREQUENCY RANGE | MERCADO, ALEXANDER A | 2855 | §102§103§112 | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18718766 | BACTERIOPHAGE LAMBDA-VACCINE SYSTEM | GILL, RACHEL B | 1671 | §112 | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18704211 | SINGLE DOMAIN ANTIBODIES TARGETING THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN | ZOU, NIANXIANG | 1671 | §112 | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18688126 | MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE | GONZALEZ, LUISALBERTO | 1624 | §102§103§112 | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18410773 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | MCCAIG, BRIAN A | 1772 | §102§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18568738 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | FETTEROLF, BRANDON J | 1626 | §102 | Non-Final OA | 16d | Pending | Dec 08, 2023 |
| 18032132 | HIGH CONCENTRATION METHYLCOBALAMIN OR COMBINATION OF METHYL- AND HYDROXY-COBALAMIN FOR THE TREATMENT OF COBALAMIN C DEFICIENCY DISORDERS | CRAIGO, BAHAR ALAWI | 1699 | §103 | Final Rejection | 44d overdue | Pending | Apr 14, 2023 |
| 17923394 | ABERRANT POST-TRANSLATIONAL MODIFICATIONS (PTMS) IN METHYL- AND PROPIONIC ACIDEMIA AND A MUTANT SIRTUIN (SIRT) TO METABOLIZE PTMS | BOWLES, DAVID PAUL | 1654 | §112 | Non-Final OA | 13d | Pending | Nov 04, 2022 |
| 17929415 | NEISSERIA MENINGITIDIS IMMUNOGENIC COMPOSITIONS | DEVI, SARVAMANGALA | 1645 | §103§112DP | Non-Final OA | — | Pending | Sep 02, 2022 |
| 18709949 | Cannabinoid Receptor Modulating Compounds | SCHMIDT, IZABELA MARIA | — | §103 | Non-Final OA | — | Pending | May 14, 2024 |
| 18627191 | COMPOUNDS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE | OLSON, ANDREA STEFFEL | 1693 | §102§103 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18697168 | NUCLEAR MAGNETIC RESONANCE METHODS OF DETERMINING HOMEOSTATIC PERTURBATIONS | XU, XIAOYUN | 1797 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18568661 | COMPOSITIONS AND METHODS FOR DETERMINING RESPONSIVENESS TO IMMUNE CHECKPOINT INHIBITORS (ICI), INCREASING EFFECTIVENESS OF ICI, AND TREATING CANCER | DICKENS, AMELIA NICOLE | 1645 | §102 | Final Rejection | — | Pending | Dec 08, 2023 |
| 18289596 | T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53 | CHANDRA, GYAN | 1674 | §112 | Non-Final OA | — | Pending | Nov 06, 2023 |
| 18042743 | METHODS TO PRODUCE VERY LONG CHAIN FATTY ACIDS (VLCFA) | DAVIS, BRIAN J | 1614 | §112 | Non-Final OA | 187d overdue | Pending | Feb 23, 2023 |
| 18705869 | USE OF CARBOXYPEPTIDASE E/NEUROTROPHIC FACTOR-ALPHA1 TO TREAT NEURODEGENERATIVE DISEASE | BARRON, SEAN C | 1653 | §103§112 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18499833 | DNA METHYLATION-BASED CANCER DIAGNOSTICS | KALLAL, ROBERT JAMES | — | §101§103§112 | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18262779 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | SEITZ, ANTHONY JOSEPH | 1629 | §102§103§112 | Non-Final OA | — | Pending | Jul 25, 2023 |
| 18605198 | VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORS | HIBBERT, CATHERINE S | 1658 | §103§112DP | Non-Final OA | — | Pending | Mar 14, 2024 |
| 17277397 | COMPOSITIONS AND METHODS FOR MODULATION OF LMNA EXPRESSION | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Final Rejection | — | Pending | Mar 18, 2021 |
| 18560035 | COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASES | WHITEMAN, BRIAN A | 1636 | §101§103§112 | Final Rejection | — | Pending | Nov 09, 2023 |
| 18026544 | CORONAVIRUS ANTIBODIES AND USES THEREOF | JADHAO, SAMADHAN JAISING | 1672 | §101 | Non-Final OA | 27d | Pending | Mar 15, 2023 |
| 18287630 | HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE | LEE, JIA-HAI | 1658 | §102§103§112 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18480306 | NK CELLS OR T CELLS EXPRESSING CHIMERIC HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE | PAULUS, ERIN VIRGINIA | 1631 | §102§112 | Non-Final OA | — | Pending | Oct 03, 2023 |
| 18035240 | MODIFIED NK CELLS WITH REDUCED CCR5 EXPRESSION AND METHODS OF THEIR USE | QIAN, CELINE X | 1637 | §103 | Final Rejection | 13d | Pending | May 03, 2023 |
| 16450825 | NOVEL CRISPR ENZYMES AND SYSTEMS | RAMIREZ, DELIA M | 1652 | §112 | Non-Final OA | 14d | Pending | Jun 24, 2019 |
| 16450699 | NOVEL CRISPR ENZYMES AND SYSTEMS | RAMIREZ, DELIA M | 1652 | §112 | Final Rejection | — | Pending | Jun 24, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUnited States Department of Health and Human Services has 37 pending office actions as of October 2026, spread across 25 art units and 34 examiners.
Brian J Davis has the most, with 2 of United States Department of Health and Human Services's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
